Free Trial
NASDAQ:SANA

Sana Biotechnology Q4 2025 Earnings Results & Report

Sana Biotechnology logo
$2.36 -0.08 (-3.09%)
As of 12:17 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Sana Biotechnology missed analyst earnings expectations in its Q4 2025 results, released March 3, 2026. The company reported EPS of -$0.16 versus the -$0.13 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens
Conference Call
3:00 PM ET

Sana Biotechnology EPS Results

Actual EPS
-$0.16
Consensus EPS
-$0.13
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

Sana Biotechnology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sana Biotechnology Q4 2025 Earnings FAQ

Sana Biotechnology (NASDAQ:SANA) reported earnings of -$0.16 per share for Q4 2025, missing the consensus estimate of -$0.13. The report was announced on Tuesday, March 3, 2026.

Sana Biotechnology Earnings Headlines

The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
Sana Biotechnology: A Shot At Diabetes
See More Sana Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sana Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sana Biotechnology and other key companies, straight to your email.

About Sana Biotechnology

Sana Biotechnology (NASDAQ:SANA) is a clinical-stage biotechnology company founded in 2018 and headquartered in Seattle. It develops engineered cells intended to treat a range of diseases, including cancer, autoimmune disorders and conditions that may be addressed through cell replacement.

The company’s research focuses on modifying cells to improve their therapeutic properties, including approaches designed to help transplanted cells evade immune rejection. Its programs include engineered immune-cell therapies and cell-replacement treatments, such as work involving insulin-producing cells for type 1 diabetes. These are investigational programs, not approved products.

Sana conducts research and development in the United States, with locations including Seattle, South San Francisco and Cambridge. Its chief executive officer is Steve Harr.

View Sana Biotechnology Profile